The members of the AMYPAD initiative proudly announce the recruitment of their first research participant.
The first participant was recruited in Geneva, Switzerland. He now takes part of the diagnostic and patient management sub-study. In this clinical study, researchers aim to include subjects suspected of possible Alzheimer’s disease. They aim to determine the usefulness of β-amyloid imaging as a diagnostic marker for Alzheimer’s disease. To do so, the study will involve people with dementia, people with mild cognitive impairment and subjective cognitive decline. This will enable the researchers to study the impact of β-amyloid PET on both diagnostic confidence, patient management and resource utilisation.
“Anyone would agree that amyloid PET accurately reflects brain amyloidosis, but to what extent this information addresses patients’ needs and expectations rather than physicians’ and industry’s is a contentious subject that AMYPAD DPMS will provide an answer to.”
Prof. Giovanni Frisoni (pictured), group leader of the laboratory of neuroimaging of aging at the University of Geneva.
AMYPAD is a 5-year large-scale study. It involves 15 organisations including academic and industrial partners, SMEs and patient organisations.
For further information, visit www.amypad.eu or please contact: email@example.com